The Library
The cost‐effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding : an economic evaluation based on the PRISM trial
Tools
Tools
Tools
(2020) The cost‐effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding : an economic evaluation based on the PRISM trial. BJOG: An International Journal of Obstetrics & Gynaecology, 127 (6). pp. 757-767. doi:10.1111/1471-0528.16068 ISSN 1471-0528.
|
PDF
WRAP-cost-effectiveness-progesterone-miscarriages-women-pregnancy-bleeding-economic-PRISM trial-Quenby-2020.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (528Kb) | Preview |
Official URL: https://doi.org/10.1111/1471-0528.16068
Abstract
Objectives
To assess the cost‐effectiveness of progesterone compared with placebo in preventing pregnancy loss in women with early pregnancy vaginal bleeding.
Design
Economic evaluation alongside a large multi‐centre randomised placebo‐controlled trial.
Setting
Forty‐eight UK NHS early pregnancy units.
Population
Four thousand one hundred and fifty‐three women aged 16–39 years with bleeding in early pregnancy and ultrasound evidence of an intrauterine sac.
Methods
An incremental cost‐effectiveness analysis was performed from National Health Service (NHS) and NHS and Personal Social Services perspectives. Subgroup analyses were carried out on women with one or more and three or more previous miscarriages.
Main outcome measures
Cost per additional live birth at ≥34 weeks of gestation.
Results
Progesterone intervention led to an effect difference of 0.022 (95% CI −0.004 to 0.050) in the trial. The mean cost per woman in the progesterone group was £76 (95% CI −£559 to £711) more than the mean cost in the placebo group. The incremental cost‐effectiveness ratio for progesterone compared with placebo was £3305 per additional live birth. For women with at least one previous miscarriage, progesterone was more effective than placebo with an effect difference of 0.055 (95% CI 0.014–0.096) and this was associated with a cost saving of £322 (95% CI −£1318 to £673).
Conclusions
The results suggest that progesterone is associated with a small positive impact and a small additional cost. Both subgroup analyses were more favourable, especially for women who had one or more previous miscarriages. Given available evidence, progesterone is likely to be a cost‐effective intervention, particularly for women with previous miscarriage(s).
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RG Gynecology and obstetrics |
||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||
| SWORD Depositor: | Library Publications Router | ||||||||
| Library of Congress Subject Headings (LCSH): | Miscarriage, Miscarriage -- Prevention, Progesterone, Progesterone -- Cost effectiveness | ||||||||
| Journal or Publication Title: | BJOG: An International Journal of Obstetrics & Gynaecology | ||||||||
| Publisher: | Wiley | ||||||||
| ISSN: | 1471-0528 | ||||||||
| Official Date: | May 2020 | ||||||||
| Dates: |
|
||||||||
| Volume: | 127 | ||||||||
| Number: | 6 | ||||||||
| Page Range: | pp. 757-767 | ||||||||
| DOI: | 10.1111/1471-0528.16068 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | Published | ||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||
| Date of first compliant deposit: | 12 October 2020 | ||||||||
| Date of first compliant Open Access: | 14 October 2020 | ||||||||
| RIOXX Funder/Project Grant: |
|
||||||||
| Is Part Of: | 1 | ||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
